O'Brien T P, Sawusch M R, Dick J D, Gottsch J D
Wilmer Ophthalmological Institute, Johns Hopkins Hospital, Baltimore, MD 21205.
Arch Ophthalmol. 1988 Oct;106(10):1444-6. doi: 10.1001/archopht.1988.01060140608032.
Ciprofloxacin is a new quinolone antibiotic that is highly active in vitro against Pseudomonas aeruginosa. A rabbit model of bacterial keratitis was used to assess the in vivo efficacy of topical ciprofloxacin. Albino rabbits received intrastromal injections of 5 X 10(2) aminoglycoside-resistant P aeruginosa organisms. At five hours after inoculation, ciprofloxacin (3 mg/mL) therapy was initiated (one drop every 30 minutes for 12 hours). Corneal tissue was then excised for bacterial colony counts. No organisms were recovered from ciprofloxacin-treated eyes, compared with an average of 3.1 X 10(7) organisms per milliliter recovered from untreated controls. This model suggests that topical ciprofloxacin may be clinically useful in the treatment of aminoglycoside-resistant P aeruginosa keratitis.
环丙沙星是一种新型喹诺酮类抗生素,在体外对铜绿假单胞菌具有高度活性。采用兔细菌性角膜炎模型评估局部应用环丙沙星的体内疗效。白化兔接受基质内注射5×10²耐氨基糖苷类铜绿假单胞菌。接种后5小时开始环丙沙星(3mg/mL)治疗(每30分钟滴一滴,共12小时)。然后切除角膜组织进行细菌菌落计数。与未治疗的对照组每毫升平均回收3.1×10⁷个细菌相比,环丙沙星治疗的眼中未回收任何细菌。该模型表明局部应用环丙沙星在治疗耐氨基糖苷类铜绿假单胞菌角膜炎方面可能具有临床应用价值。